GlassScriptPhysician profile
Nichole Fuller
NPI 1720584899
$4,079.47
in general payments reported to CMS, 2019-2025
27 companies · $759 in 2025
The $759 reported for 2025 was more than what 84% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $659 · 2023: $1,021 · 2024: $1,355 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $878.85 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $626.48 | 2021-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $432.50 | 2023-2025 | Assure Wcd |
| Novo Nordisk INC | $259.13 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $241.06 | 2022-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.44 | 2021-2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $171.06 | 2024 | Optimizer |
| Recor Medical INC | $154.02 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Actelion Pharmaceuticals US, INC. | $120.43 | 2024-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $114.99 | 2023-2025 | Verquvo |
| Boston Scientific Corporation | $109.80 | 2024 | Watchman Flx |
| Lilly USA, LLC | $107.57 | 2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $102.78 | 2022-2024 | |
| Bridgebio Pharma, INC. | $95.36 | 2025 | Attruby |
| Abbott Laboratories | $90.40 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $53.50 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.91 | 2022-2024 | |
| Cardiva Medical, INC. | $47.30 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Cvrx, INC. | $44.85 | 2023-2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $27.73 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $23.27 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $21.71 | 2024 | |
| Pfizer INC. | $18.99 | 2025 | |
| Daiichi Sankyo INC. | $18.21 | 2023 | Injectafer |
| Baxter Healthcare | $12.84 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Biotronik INC. | $12.79 | 2021 | |
| Amgen INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichole Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.